Leptomeningeal Carcinomatosis in Gastric Cancer: A Therapeutical Challenge

Vergoulidou, Maria

doi:10.1177/1177271917695237

Cited by 15 publications

(19 citation statements)

References 31 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GC and EC have high incidence and mortality, representing the fifth and seventh most common cancers and the third and fifth causes of cancer-related deaths worldwide, respectively 1 2. Common metastatic sites are liver and peritoneum 1. However, due to increased survival with new treatments, LC incidence is rising 3 7…”

Section: Discussionmentioning

confidence: 99%

“…Prognosis is usually devastating, with median survival of 4 weeks in GC and 8 weeks in other solid tumours 1 3 8 9. Despite treatment, survival remains poor, averaging 3 to 6 months 6…”

Section: Discussionmentioning

confidence: 99%

“…Gastric cancer (GC) and esophageal cancer (EC) present high incidence and mortality rates 1 2. Leptomeningeal carcinomatosis (LC) is rare and usually occurs in melanoma, lung and breast cancers 3 4.…”

Section: Introductionmentioning

confidence: 99%

“…Leptomeningeal carcinomatosis (LC) is rare and usually occurs in melanoma, lung and breast cancers 3 4. It is very rare in other solid tumours and comprises a poor prognosis 1. Performance status (PS), age and presentation impact prognosis and treatment choice 5.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Palliative approach to leptomeningeal carcinomatosis in oesophagogastric junction cancer

et al. 2019

View full text Add to dashboard Cite

Leptomeningeal carcinomatosis (LC) is rare in solid tumours, particularly in gastrointestinal cancers. While other treatment strategies remain undefined, inclusion of palliative care is essential due to its very poor prognosis and variable manifestations. We report a case of oesophagogastric junction adenocarcinoma, previously submitted to surgery and chemotherapy, diagnosed with LC and followed in a palliative care unit. Treatment was comanaged with the oncology team and a palliative approach was decided. In this report, we review the literature and evaluate treatment options, with focus on the importance of palliative care and its potential benefits in patients diagnosed with this rare entity.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Prognosis is usually devastating, with median survival of 4 weeks in GC and 8 weeks in other solid tumours 1 3 8 9. Despite treatment, survival remains poor, averaging 3 to 6 months 6…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Palliative approach to leptomeningeal carcinomatosis in oesophagogastric junction cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…12 Currently, there are no golden standard treatment guidelines for LMC due to the lack of standardization. 13,14 Chemotherapy or RT is the important treatment option for patients with LMC, although these are performed as palliative treatments, and the resultant patient outcomes are suboptimal. 15 Although systemic chemotherapy is a crucial treatment for LMC, most anti-cancer agents have difficulty in penetrating the bloodbrain barrier.…”

Section: Discussionmentioning

confidence: 99%

Leptomeningeal carcinomatosis from gastric cancer successfully treated by the intrathecal methotrexate plus temozolomide and simultaneous radiotherapy: Case report and literatures review

Liu

2017

Cancer Biology & Therapy

View full text Add to dashboard Cite

Leptomeningeal carcinomatosis (LMC) from gastrointestinal cancer is rare. A 56-year-old man with complaint of upper abdominal pain exhibited adenocarcinoma upon histopathologic examination of biopsy specimens. At the end of adjuvant chemotherapy, the patient was affected by hearing loss. Malignant cells were observed by cerebrospinal fluid (CSF) cytology. Therefore, the patient received intrathecal methotrexate and oral temozolomide chemotherapy and radiotherapy. The progress-free survival was approximately 11 months. To our knowledge, such cases of LMC from gastric cancer are very rare. Here, we describe the case of a patient with LMC from gastric cancer and review the literature associated with treatment. We hope that the present report may be helpful when considering how to improve treatment of LMC in gastric cancer patients and offer some tips for the adjuvant treatment modality.

show abstract

Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes

Baccili Cury Megid,

Baskurt,

et al. 2024

J Neurooncol

View full text Add to dashboard Cite

Background Brain metastasis (BrM) and Leptomeningeal Carcinomatosis (LMC) are uncommon complications in gastroesophageal carcinoma (GEC) patients. These patients have a poor prognosis and are challenging to treat. We described the clinicopathologic features and outcomes in the largest cohort of Central Nervous System (CNS) metastasis in GEC patients. Methods single-center retrospective study of GEC treated from 2007 to 2021. Clinicopathologic characteristics and treatment modalities were reviewed. Survival was calculated from the date of CNS diagnosis until date of death/last follow-up using the Kaplan-Meier method. A multivariable Cox proportional hazards regression model was used. Results Of 3283 GEC patients, 100 (3.04%) were diagnosed with BrM and 20 with LMC (0.61%). Patients with known human epidermal growth factor receptor 2 (HER2) status (N = 48), 60% were HER2 positive (defined as IHC 3 + or IHC 2+/FISH+). Among LMC patients most were signet-ring subtype (85%), and only 15% (2/13) were HER2 positive. Median survival was 0.7; 3.8; and 7.7 months in BrM patients treated with best supportive care, radiation, and surgery, respectively (p < 0.001). In LMC, median survival was 0.7 month in patients who had best supportive care (7/19) and 2.8 months for those who had whole brain radiation therapy (p = 0.015). Multivariate analysis showed worse outcomes in ECOG ≥ 2 (p = 0.002), number of BrM ≥ 4 (p < 0.001) and number of metastatic sites (p = 0.009). Conclusion HER2 expression were enriched in patients with BrM, while it is uncommon in LMC. Patients treated with surgery followed by radiation had an improved OS in BrM and WBRT benefited patients with LMC.

show abstract

Leptomeningeal Carcinomatosis in Gastric Cancer: A Therapeutical Challenge

Cited by 15 publications

References 31 publications

Palliative approach to leptomeningeal carcinomatosis in oesophagogastric junction cancer

Palliative approach to leptomeningeal carcinomatosis in oesophagogastric junction cancer

Leptomeningeal carcinomatosis from gastric cancer successfully treated by the intrathecal methotrexate plus temozolomide and simultaneous radiotherapy: Case report and literatures review

Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes

Contact Info

Product

Resources

About